Alnara Pharmaceuticals Inc. is expected to announce Wednesday morning that it has licensed the Phase III cystic fibrosis drug Trizytek - which was dropped by Altus Pharmaceuticals Inc. in January - from the Cystic Fibrosis Foundation. (BioWorld Today) Read More
